Niki BioSolutions, Inc.
As of Oct 22, 2026, Niki BioSolutions is in Stage 4, the downtrend phase, now in week 10 (since Aug 19, 2026). It closed at $1.86, 88.5% below its 52-week high and below its 200-day average, which is falling.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to tr… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NIKI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NIKI among Biotechnology503rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …503 | NIKI | Stage 4 · wk 10 | 8 | −60.3% |
Niki BioSolutions: quick answers
What stage is Niki BioSolutions in?
As of Oct 22, 2026, Niki BioSolutions (NIKI) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 19, 2026 and is in week 10. What the four stages mean
Is Niki BioSolutions in an uptrend?
No. Niki BioSolutions is in a Stage 4 downtrend. It trades 76.7% below its 200-day average, which is falling.
How far is Niki BioSolutions from its 52-week high?
Niki BioSolutions closed at $1.86 on Oct 22, 2026, 88.5% below its 52-week high of $16.20. Its 52-week low is $1.86.
How has Niki BioSolutions performed over the past year?
As of Oct 22, 2026, Niki BioSolutions is down 88.4% over the past year and down 82.6% so far in 2026.
Which sector and industry is Niki BioSolutions in?
Niki BioSolutions is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.